Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022

Addex Completes $4.2 Million Equity Financing

Addex Raises $4.2 million in Equity Financing

Addex Provides Corporate Update and Financial Guidance

Addex Completes Reduction in Nominal Value of Shares

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study